Two-year OCT follow-up in multiple sclerosis patients on Ofatumumab shows retinal preservation over non-antiCD20 treatments. Greco G, Della Porta G, Masi F, Redemagni C, et al. J Neurol 2026;273:77.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Greco G, Della Porta G, Masi F, Redemagni C, et al. Two-year OCT follow-up in multiple sclerosis patients on Ofatumumab shows retinal preservation over non-antiCD20 treatments. J Neurol 2026;273:77.
PMID: 41518393